ClinicalTrialsFinder
RecruitingNCT03458520

Pediatric PET/MR Image Registry

Sponsor

Stanford University

Enrollment

100 participants

Start Date

Feb 1, 2018

Study Type

OBSERVATIONAL

Conditions

LymphomaOsteosarcomaSoft Tissue

Summary

The purpose of this study is to compare whole body magnetic resonance (MR) imaging, whole body positron emission tomography (PET)/MR imaging, and (if available) PET/Computed Tomography (CT) imaging for the diagnosis of tumors in children and young adults. Sensitivities, specificities and diagnostic accuracies of the different imaging modalities will be compared for significant differences.

Eligibility

Max Age: 40 Years

Inclusion Criteria3

  • Patients with proven solid tumors or newly diagnosed mass strongly suspected to represent a solid tumor.
  • We might also include some patients with leukemia if there is concern for a focal lesion in any of their organs.
  • Participant's parents (if participant is under 18) or the participant (if participant is 18 years or older) must willingly give written informed consent prior to any image transfer to the image registry.

Exclusion Criteria4

  • Patient has contraindications for MRI or PET/MR. This includes patients with cardiac pacemakers or intracranial vascular clips as well as patients with a blood glucose level \> 200 mg/dl.
  • Lack of parental permission (if participant is younger than 18) or lack of informed consent (if participant is at least 18 years of age).
  • Patient has a CNS primary tumor.
  • Pregnant women and fetuses

Interventions

DIAGNOSTIC_TESTPET/MR imaging

undergo PET/MR imaging

DIAGNOSTIC_TESTMR imaging

Undergo MR imaging

DIAGNOSTIC_TESTPET/CT imaging

Undergo PET/CT imaging

Locations(1)

Stanford University, School of Medicine

Palo Alto, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03458520

Related Trials

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT0685942413 locations

Apatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma

NCT074797321 location

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

NCT0233266817 locations

Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma

NCT052943671 location

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

NCT065103613 locations